Newborn Sequencing 2023 Part II: What Evidence Is Enough?

Chapters:0:00   State of the field: reviewing ICoNS conference22:20 What evidence is enough?Today, we’re joined by a panel of four guests who have all attended the recent International Conference on Newborn Sequencing held at the Royal Institution in London.  This discussion serves as the second part in a series we are co-producing with GenomeWeb that began with last month’s panel.  At the conference, researchers representing 12 newborn sequencing research programs in the US, the UK, Europe, Australia, and the Middle East discussed their progress to date and future plans.   It’s our good fortune to hear about the conference and get some thoughts on the field going forward.  Julia Karow is the Managing Editor at GenomeWeb, who tracks trends in next-gen sequencing for research and clinical applications.Robert Green is a physician-scientist who directs the Genomes2People Research Program in translational genomics and health outcomes.  He also co-chairs the International Consortium on Newborn Sequencing, the group which hosted the conference.Wendy Chung is Chair of Pediatrics in Medicine at Boston Children’s Hospital.  She directs one of the largest newborn sequencing studies,  called the Guardian Study.James Buchanan is a Senior Lecturer in Health Economics at Queen Mary University in London.  He does research into the health economics of precision medicine and genetic testing, including newborn screening. This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe